arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nautilus Biotechnology, Inc.

NAUT
$1.01 ▲ +0.05 (+5.19%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
27 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nautilus Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $128.4M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share $-0.11 ↘
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-14.47M
↑ +3.8% —
FCF / Share Free cash flow per share
$-0.11
↓ -3.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
20
Cash Quality ↑
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters